Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9), a biomarker for various pathological conditions, is produced in post-blood collection by fibrinolysis and coagulation factors

Clinical Proteomics

Wataru Kikuchi²  Motoi Nishimura¹  Sachio Tsuchida¹  Takeshi Tomonaga⁴  Fumio Nomura³  Takahisa Kuga⁵  Mamoru Satoh¹  Kenta Noda⁶  Yoshio Kodera⁷  Tatsuya Saito⁷ 

[1]Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan

[2]Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, JapanDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, JapanDepartment of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, Japan

[3]Division of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba, JapanDivision of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba, JapanDivision of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba, Japan

[4]Laboratory of Proteome Research, National Institute of Biomedical Innovation, Osaka, JapanLaboratory of Proteome Research, National Institute of Biomedical Innovation, Osaka, JapanLaboratory of Proteome Research, National Institute of Biomedical Innovation, Osaka, Japan

[5]Department of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, JapanDepartment of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, JapanDepartment of Biochemistry and Molecular Biology, Kyoto Pharmaceutical University, Kyoto, Japan

[6]R&D Department, Nittobo Medical Co., Ltd., Koriyama, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, JapanR&D Department, Nittobo Medical Co., Ltd., Koriyama, Japan

[7]Department of Physics, School of Science, Kitasato University, Sagamihara, JapanDepartment of Physics, School of Science, Kitasato University, Sagamihara, JapanDepartment of Physics, School of Science, Kitasato University, Sagamihara, Japan

关键词: Biomarker;    Fibrinogen;    Plasmin;    Thrombin;    Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9);    Coagulation;    Hepatitis;   

DOI  :  10.1186/s12014-016-9129-6

来源: Humana Press Inc

【 摘 要 】

Abstract

Background

Fibrinogen alpha C chain 5.9 kDa fragment (FIC5.9) is a new serum biomarker for chronic hepatitis that was discovered by proteomics analysis. Previous studies have shown that FIC5.9 is derived from the C-terminal region of fibrinogen alpha chain and the serum levels of FIC5.9 decrease in chronic hepatitis. It also have been reported that FIC5.9 cannot be detected in the blood stream of the systemic circulation and it is released from fibrinogen during blood clotting in collecting tube. However, the mechanism of FIC5.9 releasing from fibrinogen is unclear.

Methods

We formulated a hypothesis that FIC5.9 is released by enzymes that are activated by post-blood collection and may be coagulation and fibrinolysis factors. In this study, we analyzed the mechanisms of FIC5.9 releasing from fibrinogen in healthy blood.

Results

Our analysis showed that thrombin acts as an initiator for FIC5.9 releasing, and that mainly plasmin cleaves N-terminal end of FIC5.9 and neutrophil elastase cleave C-terminal end of FIC5.9.

Conclusion

FIC5.9 reflects minute changes in coagulation and fibrinolysis factors and may be associated with pathological conditions.

【 授权许可】

Unknown